Shots:

• Senti Bio to receive up front and funding to support its research activities. If Spark exercises the option- Senti Bio will be eligible to receive an option exercise payment- development- regulatory- and sales milestone along with royalties per product which may exceed $645M
• Senti Bio will lead designing- building- and testing cell type and disease specific-synthetic promoters for use in CNS- ocular or liver-directed gene therapies
• Spark to get an option to exclusively license synthetic promoters emerges from collaboration to develop gene therapy products in the specified indications. Upon option exercise- Spark will lead pre/ clinical- and commercialization activities for gene therapy candidates incorporating Senti Bio’s licensed synthetic promoters

  Ref: GlobeNewswire | Image: Fierce Biotech